Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07007091 · ClinicalTrials.gov registry record · Phase 1

A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administrations With a Pre-Filled Syringe or an On-Body Injector in Healthy Adult Participants

A Phase 1 study of Healthy Volunteers, sponsored by AbbVie.

Completed
Registry status
Phase 1
Development phase
260
Enrollment target
4
Study locations

NCT07007091: Completed Phase 1 study of Healthy Volunteers, sponsored by AbbVie.

NCT07007091 is a Phase 1 study of Healthy Volunteers that has completed, run by AbbVie. The registered enrollment target is 260 participants, below the 481-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (46% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07007091, a Phase 1 study of Healthy Volunteers, has completed, sponsored by AbbVie.

COMPLETED
Registry status
Phase 1
Development phase
260 participants
Enrollment target
4
Study locations

Study Summary

This study will assess the pharmacokinetics and relative Bioavailability of risankizumab following subcutaneous administration with an on-body injector relative to a prefilled syringe

Primary Outcome

Maximum observed plasma concentration (Cmax) of Risankizumab

Conditions Studied

Interventions

  • DRUG Risankizumab

Study Locations (4)

Florida

  • Cpmi /Id# 276490 - Miami

Illinois

  • Acpru /Id# 276043 - Grayslake

Nevada

  • Ppd - Las Vegas Research Unit /ID# 276565 - Las Vegas

Texas

  • PPD Phase I Clinic /ID# 276525 - Austin

Trial Details

FieldValue
Enrollment Target 260 participants
Start Date 2025-06-12
Est. Completion 2026-01-15
Phase Phase 1
AbbVie

526 total trials

What the finished NCT07007091 record still lists

NCT07007091 is an interventional study that assigns participants to a tested intervention. The registered 260 participants enrollment target is mid-sized for trials with a published cap, below the 481-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (46% lower).

The record links to 1 condition, with Healthy Volunteers appearing as the primary indexed condition, and to 1 intervention - of which Risankizumab is the first listed.

NCT07007091 reports a single indexed study location in Florida, Illinois, Nevada.

Frequently Asked Questions

What is clinical trial NCT07007091 about?

NCT07007091 is a clinical study titled "A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administrations With a Pre-Filled Syringe or an On-Body Injector in Healthy Adult Participants". This study will assess the pharmacokinetics and relative Bioavailability of risankizumab following subcutaneous administration with an on-body injector relative to a prefilled syringe

What is the current status of trial NCT07007091?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 260 participants. The study started on 2025-06-12. Estimated completion is 2026-01-15.

What conditions does trial NCT07007091 study?

This clinical trial studies the following conditions: Healthy Volunteers.

What interventions are being tested in trial NCT07007091?

The interventions under investigation include: Risankizumab (DRUG).

Who is sponsoring clinical trial NCT07007091?

This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07007091 being conducted?

This trial has 4 study locations across Florida, Illinois, Nevada, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Volunteers

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07007091's enrollment target sits among peer trials

260 39th of 283 higher than 245 of 283 other Healthy Volunteers trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy Volunteers trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02283996 · 260 participants · Phase 4

    Adhesive Capsulitis: Prospective Analysis of Efficacy and Financial Impact for Use of Physical Therapy in Treatment

  • NCT03276793 · 260 participants · NA

    Brain Connectivity in Depression

  • NCT03407469 · 260 participants

    Measurement of Adherence and Health-Related Quality of Life, and Health-Care Resource Utilization

  • NCT03713125 · 260 participants · NA

    Executive Function in Early Childhood

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07007091, the US trial registry maintained by the National Library of Medicine. NCT07007091 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.